Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imaging immunity in patients with cancer using positron emission tomography.
Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP. Hegi-Johnson F, et al. NPJ Precis Oncol. 2022 Apr 7;6(1):24. doi: 10.1038/s41698-022-00263-x. NPJ Precis Oncol. 2022. PMID: 35393508 Free PMC article. Review.
Radiotherapy toxicity.
De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. De Ruysscher D, et al. Nat Rev Dis Primers. 2019 Feb 21;5(1):13. doi: 10.1038/s41572-019-0064-5. Nat Rev Dis Primers. 2019. PMID: 30792503 Review.
Author Correction: Radiotherapy toxicity.
De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. De Ruysscher D, et al. Nat Rev Dis Primers. 2019 Mar 4;5(1):15. doi: 10.1038/s41572-019-0073-4. Nat Rev Dis Primers. 2019. PMID: 30833595
Overcoming immunotherapy resistance in NSCLC.
MacManus M, Hegi-Johnson F. MacManus M, et al. Lancet Oncol. 2022 Feb;23(2):191-193. doi: 10.1016/S1470-2045(21)00711-7. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033225 No abstract available.
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. Hegi-Johnson F, et al. BMJ Open. 2022 Nov 18;12(11):e056708. doi: 10.1136/bmjopen-2021-056708. BMJ Open. 2022. PMID: 36400733 Free PMC article. Clinical Trial.
Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo.
Wichmann CW, Poniger S, Guo N, Roselt P, Rudd SE, Donnelly PS, Blyth B, Van Zuylekom J, Rigopoulos A, Burvenich IJG, Morandeau L, Mohamed S, Nowak AK, Hegi-Johnson F, MacManus M, Scott AM. Wichmann CW, et al. Nucl Med Biol. 2023 May-Jun;120-121:108351. doi: 10.1016/j.nucmedbio.2023.108351. Epub 2023 May 16. Nucl Med Biol. 2023. PMID: 37224789 Free article.
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
Hegi-Johnson F, Rudd SE, Wichmann CW, Akhurst T, Roselt P, Sursock S, Trinh J, John T, Devereux L, Donnelly PS, Hicks RJ, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. Hegi-Johnson F, et al. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):675-682. doi: 10.1016/j.ijrobp.2023.05.019. Epub 2023 Jul 3. Int J Radiat Oncol Biol Phys. 2023. PMID: 37406824 No abstract available.
30 results